You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲頂新耀-B(01952.HK):TrodelvyTM (sacituzumab govitecan)用於治療轉移性乳腺癌的亞洲3期臨試完成首例患者給藥
格隆匯 12-09 16:36

格隆匯 12 月 9日丨雲頂新耀-B(01952.HK)發佈公告,TrodelvyTM(“sacituzumab govitecan”)用於治療轉移性乳腺癌的亞洲3期臨牀試驗完成首例患者給藥,該研究用於評估該藥在治療激素受體陽性(“HR+”)╱人表皮生長因數受體2陰性(“HER2-”)轉移性乳腺癌(“mBC”)與醫生選擇的治療方案(“TPC”)的對比。

EVER-132-002是一項亞洲3期研究,旨在評估和比較sacituzumab govitecan與醫生選擇的治療方案對接受過至少兩種但不超過四種系統性化療的HR+ ╱ HER2-轉移性乳腺癌亞洲患者的安全性和有效性。此試驗將在中國大陸、中國台灣和韓國招募330名HR+ ╱ HER2- 的轉移性乳腺癌患者,主要終點是由獨立評審委員會根據RECIST v1.1(實體瘤療效評價標準1.1)評價的無進展生存期。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account